Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Ardelyx (NASDAQ: ARDX) has scheduled its first quarter 2025 financial results conference call for Thursday, May 1, 2025, at 4:30 p.m. Eastern Time. The biopharmaceutical company will discuss Q1 2025 financial performance and provide a business update during the call.
Investors can participate by dialing (877) 346-6112 (domestic) or (848) 280-6350 (international). A live audio webcast will be available on the Investors section of Ardelyx's website at www.ardelyx.com, with a 30-day replay period following the call.
Ardelyx (NASDAQ: ARDX) ha programmato la conference call per la presentazione dei risultati finanziari del primo trimestre 2025 per giovedì 1 maggio 2025 alle 16:30, ora della costa orientale degli Stati Uniti. La società biofarmaceutica discuterà delle performance finanziarie del primo trimestre 2025 e fornirà un aggiornamento sul business durante la chiamata.
Gli investitori potranno partecipare chiamando il numero (877) 346-6112 (nazionale) o (848) 280-6350 (internazionale). Una trasmissione audio in diretta sarà disponibile nella sezione Investitori del sito web di Ardelyx all'indirizzo www.ardelyx.com, con la possibilità di riascolto per 30 giorni dopo la chiamata.
Ardelyx (NASDAQ: ARDX) ha programado su llamada de conferencia para los resultados financieros del primer trimestre de 2025 el jueves 1 de mayo de 2025 a las 4:30 p.m., hora del Este. La compañía biofarmacéutica discutirá el desempeño financiero del primer trimestre de 2025 y ofrecerá una actualización comercial durante la llamada.
Los inversionistas pueden participar marcando (877) 346-6112 (nacional) o (848) 280-6350 (internacional). Habrá una transmisión de audio en vivo disponible en la sección de Inversionistas del sitio web de Ardelyx en www.ardelyx.com, con un periodo de repetición de 30 días después de la llamada.
Ardelyx (NASDAQ: ARDX)는 2025년 5월 1일 목요일 동부 표준시 오후 4시 30분에 2025년 1분기 재무 실적 컨퍼런스 콜을 예정하고 있습니다. 이 바이오제약 회사는 콜 동안 2025년 1분기 재무 성과와 사업 현황에 대해 논의할 예정입니다.
투자자들은 국내 전화번호 (877) 346-6112 또는 국제 전화번호 (848) 280-6350으로 참여할 수 있습니다. Ardelyx 웹사이트(www.ardelyx.com)의 투자자 섹션에서 실시간 오디오 웹캐스트가 제공되며, 콜 이후 30일 동안 다시 듣기 서비스가 가능합니다.
Ardelyx (NASDAQ : ARDX) a programmé sa conférence téléphonique sur les résultats financiers du premier trimestre 2025 le jeudi 1er mai 2025 à 16h30, heure de l’Est. La société biopharmaceutique discutera des performances financières du premier trimestre 2025 et fournira une mise à jour commerciale lors de l’appel.
Les investisseurs peuvent participer en composant le (877) 346-6112 (domestique) ou le (848) 280-6350 (international). Une diffusion audio en direct sera disponible dans la section Investisseurs du site web d’Ardelyx à l’adresse www.ardelyx.com, avec une période de rediffusion de 30 jours après l’appel.
Ardelyx (NASDAQ: ARDX) hat seine Telefonkonferenz zu den Finanzergebnissen des ersten Quartals 2025 für Donnerstag, den 1. Mai 2025, um 16:30 Uhr Eastern Time angesetzt. Das biopharmazeutische Unternehmen wird während des Calls die finanzielle Leistung des ersten Quartals 2025 besprechen und ein Geschäftsupdate geben.
Investoren können teilnehmen, indem sie (877) 346-6112 (national) oder (848) 280-6350 (international) anrufen. Ein Live-Audio-Webcast wird im Investor-Bereich der Ardelyx-Website unter www.ardelyx.com verfügbar sein, mit einer 30-tägigen Wiederholungsfrist nach dem Call.
- None.
- None.
Conference call scheduled for 4:30 p.m. Eastern Time
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025.
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When will Ardelyx (ARDX) release Q1 2025 earnings?
How can investors join the Ardelyx (ARDX) Q1 2025 earnings call?
How long will Ardelyx (ARDX) Q1 2025 earnings call webcast be available?
Where can I find the Ardelyx (ARDX) Q1 2025 earnings webcast?
